Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $85M

Overview

A proteomics-driven platform biotech using AI to discover novel biologic drugs against challenging disease targets.

OncologyImmunology

Technology Platform

Integrated proteomics and AI platform that maps disease-relevant protein interactions to design novel antibody and protein-based therapeutics.

Funding History

1
Total raised:$85M
Series A$85M

Opportunities

Potential to unlock a new generation of biologic drugs against previously undruggable targets, creating immense value through platform validation and partnerships.

Risk Factors

Risk that its platform fails to produce clinically viable drug candidates, or that its AI models do not translate from in silico predictions to real-world biology.

Competitive Landscape

Competes with other AI-driven drug discovery platforms and large biotechs with internal proteomics capabilities to identify novel biologic drug targets.